相关实验视频
Updated: Jun 5, 2025

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
Published on: May 16, 2020
与免疫检查点抑制剂相关的心脏毒性:系统性审查和元分析
Lavinia Piazza1, Anna Carollo2, Enrica Di Martino2
1Università degli Studi di Milano, Department of Pharmacy, Italy.
免疫检查点抑制剂 (ICI),如PD-1,PD-L1和CTLA-4疗法,增加心脏毒性风险. 早期的心脏查对于管理潜在的并发症和改善癌症治疗期间患者的结果至关重要.
科学领域:
- 在瘤学瘤学.
- 心脏病学 心脏病学
- 免疫治疗是一种免疫疗法.
背景情况:
- 针对PD-1,PD-L1和CTLA-4的免疫检查点抑制剂 (ICI) 在癌症治疗中至关重要.
- 心脏毒性是这些治疗的公认但可能被低估的不良影响.
研究的目的:
- 系统地审查和评估接受批准PD-1,PD-L1和CTLA-4抑制剂的患者心脏毒性风险.
- 量化与ICI治疗相关的心脏不良事件的发生率和类型.
主要方法:
- 对2272篇文章进行系统审查.
- 包括11个II期和III期临床试验.
- 对5463名患者心脏不良事件的分析.
主要成果:
- 报告了175个心脏不良事件.
- 心房动是最常见的 (12%),其次是心脏骤停和失败 (6%).
- 治疗ICI显著增加了心脏毒性风险 (RR=1.62,OR=1.71).
结论:
- 与ICI相关的心脏毒性的发生频率和严重程度被低估了.
- 系统的心脏病查是必要的,以检测和管理潜在的心脏并发症.
- 积极的心脏监测可以优化接受ICI的患者的治疗结果.
更多相关视频
06:07Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood
Published on: February 5, 2020
06:08Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
Published on: February 10, 2023
相关概念视频
Heart Failure Drugs: Inotropic Agents
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Tumor Immunotherapy
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Heart Failure Drugs: Diuretics